Latest studies
- AuthorisedTherapeutic exploratory (Phase II)
Treatment of frontal fibrosing alopecia with microneedling and photodynamic therapy using 5-aminolevulinic acid in male and female adult participants – an open single group phase 2 study
This study is looking into a new way to treat Frontal Fibrosing Alopecia (hair loss on the front of the scalp) using microneedling and a special cream with light. It aims to see if this treatment can reduce redness and skin thickening in adults.
Frontal fibrosing alopecia (FFA)Norway - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to assess the effect of CC-95251 alone and in combination with anti-cancer drugs in subjects with Acute Myeloid Leukemia and Myelodysplastic Syndromes
This study is looking at a new medicine called CC-95251 for people with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Researchers want to see how safe it is and if it works well, both on its own and with other cancer drugs.
Acute Myeloid Leukemia and Myelodysplastic SyndromesNorway - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma
This study is for adults in the UK with a type of cancer called follicular lymphoma that has come back or not responded to previous treatments. It investigates a new cell therapy called tisagenlecleucel to see how well it works and if it's safe.
Adult patients with refractory or relapsed follicular lymphomaNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
This study looks at a new combination of medicines (A+AVD) compared to a standard treatment (ABVD) for advanced Hodgkin Lymphoma. It aims to see if the new combination can better control the cancer and help people live longer.
Advanced Classical Hodgkin LymphomaNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
This study looks at a new combination treatment for advanced melanoma that has been removed by surgery. It compares two drugs given together (nivolumab and relatlimab) against nivolumab alone, to see if the combination can help prevent the cancer from coming back.
Participants with completely resected Stage III or Stage IV melanomaNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE)
This study is testing a new medicine called semaglutide for people with early Alzheimer's disease. Researchers want to see if it can help improve memory and thinking, and how safe it is to use.
Mild cognitive impairment (MCI) or mild dementiaboth of the Alzheimer’s typeNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum Based Chemotherapy with Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL 1L)
This study looks at a new combination treatment for advanced lung cancer (non-small cell lung cancer). It compares two medicines, Niraparib and Pembrolizumab, with Pembrolizumab alone, to see if the combination helps people live longer or keeps their cancer from growing for longer.
Lung CancerNon-Small CellNorway - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase I Study of INCB099280 in Combination With Ipilimumab in Participants With Selected Solid Tumors
This early-stage study is testing a new drug, INCB099280, combined with an existing cancer treatment, YERVOY, for solid tumours. Researchers want to see if this combination causes any serious side effects and how much of the new drug stays in the body. It's a first step to understand safety.
Solid tumorNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression FORTITUDE-101)
This study looks at a new drug, bemarituzumab, for advanced stomach or gullet cancer that hasn't been treated before. It aims to see if adding bemarituzumab to standard chemotherapy helps people live longer and improves their quality of life compared to chemotherapy alone.
Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpressionNorway - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
This study is looking at a new treatment for advanced cancers. We're testing a new drug, BMS-986016, alone and with an existing cancer drug, Nivolumab, to see how safe and effective they are. It's a key first step in understanding these potential new treatments.
Neoplasms by siteNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-Center, Open Label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)
This study is looking at a medicine called Viltolarsen for boys with Duchenne Muscular Dystrophy (DMD) who can still walk. It aims to check if the medicine is safe and if it helps them. This is an ongoing study where participants who have been in previous trials can continue with the treatment.
Duchenne Muscular Dystrophy (DMD)Norway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (Oberon)
This study is looking at a new medicine called Tozorakimab for people with COPD. It aims to see if it can reduce severe flare-ups and if it's safe. Participants will be compared to those taking a dummy medicine.
Chronic Obstructive Pulmonary Disease (COPD)Norway - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s Disease
This study is testing a new medicine called GSK4527226 (also known as AL101) for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and if it can help improve memory and thinking compared to a dummy treatment.
Alzheimer's DiseaseNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
This study is looking at new ways to treat bladder cancer that has spread or can't be removed with surgery. It compares a new combination of medicines with standard chemotherapy to see which works best at helping people live longer. Participants will be randomly assigned to different treatment groups.
Untreated Unresectable or Metastatic Urothelial CancerNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(21824) A phase 3, single group treatment, open-label study to evaluate the safety of BAY 94-9027 infusions for prophylaxis and treatment of bleeding in previously treated children aged 7 to <12 years with severe hemophilia A
This study is testing a new medicine called Jivi for boys aged 7-11 with severe haemophilia A. It's looking at how safe Jivi is, whether it causes strong reactions, or if the body develops resistance to it, specifically during the first four doses.
Severe hemophilia A (<1% FVIII:C)Norway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children 3 to <18 Years of Age with Achondroplasia: PROPEL 3
This study is testing a new medicine, Infigratinib, for children aged 3 to under 18 with achondroplasia. It aims to see if the medicine helps children grow taller and improves other health aspects, compared to a dummy pill.
AchondroplasiaNorway - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients with KIT altered hematologic malignancies
This study is looking at a new drug, BLU-263, for a rare blood cancer called Advanced Systemic Mastocytosis. It will be tested alone and with another drug, azacitidine, to see how safe it is and how well it works.
Advanced Systemic MastocytosisNorway - Ongoing, recruitingTherapeutic use (Phase IV)
Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on eptinezumab treatment to brief education intervention, for the preventive treatment of migraine in patients with a dual diagnosis of migraine and Medication Overuse Headache.
This study looks at a medicine called VYEPTI for people who get frequent migraines and also over-use headache pain relievers. It compares VYEPTI plus headache education to a dummy treatment plus education, to see if VYEPTI helps reduce headache days.
Chronic MigraneMigraneMedication Overuse HeadacheNorway - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery
This study is testing a new experimental drug, CC-90010, alongside standard treatments for a type of brain cancer called glioblastoma. It's for adults whose brain tumour has been recently diagnosed and surgically removed, either fully or in part, to see if the new drug can help.
Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resectionNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
CA209-8HW A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has specific genetic changes (MSI-H or dMMR). It compares them to standard chemotherapy to see which is better at stopping the cancer from growing.
Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)Norway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP).
This study is testing a new medicine called rilzabrutinib for adults with a blood condition called Immune Thrombocytopenia (ITP). It compares the new medicine to a dummy treatment to see if it can help increase blood platelet counts and improve quality of life.
Immune Thrombocytopenia (ITP)Norway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Open-Label Study of Pralsetinib versus Standard Of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer
This study is looking at a new drug called Pralsetinib for advanced lung cancer where a specific genetic change (RET fusion) is present. It compares Pralsetinib to standard treatments to see if it works better or has fewer side effects for people who haven't had treatment for this type of cancer before.
RET fusion−positivemetastatic Non-Small Cell Lung CancerNorway - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)
This study is testing a new medicine, PTC857, for people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease. We want to see if it helps improve daily activities and how safe it is compared to a dummy medicine.
Amyotrophic Lateral SclerosisNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at High Risk for Cardiovascular Disease, on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction (LIBerate-OLE)
This study looks at a new drug, Lerodalcibep (LIB003), for people with very high cholesterol that's hard to control. It's an extension of previous studies, checking if the drug keeps working and remains safe over a longer time to help reduce 'bad' cholesterol.
Patients With Homozygous and Heterozygous Familial HypercholesterolemiaCardiovascular Diseaseor at High Risk for Cardiovascular DiseaseNorway - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, randomised, open label, multicentre study to evaluate efficacy and safety of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in patients with peritoneal carcinomatosis from colorectal carcinoma following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
This study is testing a new treatment for bowel cancer that has spread to the tummy lining. It's for people who have already had surgery and chemotherapy. Researchers want to see if the new treatment, called Radspherin, can stop the cancer from growing back and if it's safe.
Carcinomatosis of peritoneal cavityNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM
This study is testing a new medicine, Alnuctamab, for people in the UK with multiple myeloma whose cancer has come back or isn't responding to other treatments. Researchers want to see if Alnuctamab works better and is safer than current treatments, aiming to stop the cancer from growing for longer.
Relapsed and/or Refractory Multiple MyelomaNorway - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
To Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
This study is looking at a new treatment called XMAB24306, given with an existing medicine called daratumumab. It's for people in the UK who have multiple myeloma that has come back or isn't responding well to other treatments. The main aim is to check if the new combination is safe and how the body handles it.
Relapsed/Refractory Multiple MyelomaNorway - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)
This study looks at new treatments for head and neck cancer that has come back or spread after previous therapies. It compares a new drug, Lenvatinib, alone or with Pembrolizumab, against standard chemotherapy. We want to see if these new approaches help people live longer and improve their health.
Recurrent or metastatic squamous cell carcinoma of the head and neckNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on subjects with Ataxia-Telangiectasia.
This study is looking for children and adults with Ataxia-Telangiectasia (A-T) to see if a new treatment called EryDex can help with their symptoms. It compares EryDex to a dummy treatment (placebo) to find out if it's effective and safe.
Ataxia TelangiectasiaNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
BMS CV027-031, A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
This study is looking at a new medicine called Mavacamten for adults with a heart condition called non-obstructive hypertrophic cardiomyopathy. It aims to see if the medicine can make people feel better and improve their exercise ability over 48 weeks.
Non-obstructive Hypertrophic CardiomyopathyNorway - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerative Colitis or Crohn’s Disease (RELIEVE UCCD)
This study is testing a new medicine called TEV-48574 for adults with moderate to severe Crohn's disease or ulcerative colitis. It aims to see how well it works, if it's safe, and how the body handles it, comparing it to a dummy medicine.
Crohn’s diseaseUlcerative colitisNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
INCMGA 0012-303: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
This study is testing a new medicine, retifanlimab, alongside standard chemotherapy for anal canal cancer that has spread or come back. Researchers want to see if this new combination helps patients live longer without their cancer getting worse, compared to chemotherapy alone.
Squamous Carcinoma of the Anal CanalNorway - Ongoing, recruitingTherapeutic use (Phase IV)
Strategies towards personalised treatment in Juvenile Idiopathic Arthritis (JIA): An open randomised multicentre blinded-assessor trial assessing the effectiveness of intraarticular glucocorticoid injections in JIA patients starting tumour necrosis factor inhibitor treatment. The MyJIA trial.
This study, called MyJIA, looks at how well a steroid injection into joints works for children with juvenile idiopathic arthritis (JIA) who are also starting a new medicine called a TNF inhibitor. It wants to see if this combined approach helps them stay well for longer.
Juvenile Idiopathic ArthritisNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer (KEYFORM-007)
This study looks at a new drug combination, MK-4280A, for bowel cancer that has spread and has been treated before. It compares this new treatment to standard care to see if it helps people live longer and improves their quality of life.
Colorectal CancerNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
This study compares a new cell therapy (Tisagenlecleucel) with standard treatments for adults with an aggressive type of lymphoma that has come back or not responded to previous therapy. Researchers want to see which treatment is better at stopping the cancer from growing.
Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomaNorway - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
An exploratory study to investigate the effect of FE 999302 when given together with follitropin delta during controlled ovarian stimulation
This study looks at a new medicine, FE 999302, given with a common fertility drug, follitropin delta. It's for women having IVF or similar treatments to help them get pregnant. We want to see how these medicines work together.
Infertility in women undergoing assisted reproductive technologies (ART)Norway - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2/3, adaptive, randomized, open-label, clinical study to evaluate neoadjuvant and adjuvant V940 (mRNA-4157) in combination with pembrolizumab (MK-3475) versus standard of care, and pembrolizumab monotherapy in participants with resectable locally advanced cutaneous squamous cell carcinoma (LA cSCC) (INTerpath-007).
This study is looking at a new treatment for a type of skin cancer called cutaneous squamous cell carcinoma (cSCC). It combines a new vaccine (mRNA-4157) with an existing drug (pembrolizumab) to see if it works better than standard care for people whose cancer can be removed by surgery.
The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).Norway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia
This study is looking at a new medicine called Calquence for people with chronic lymphocytic leukemia. Researchers want to see how safe the medicine is by tracking any side effects. They will also check if it helps people get better.
Chronic lymphocytic leukemiaNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11/GOG-3047)
This study is testing a new treatment combination for locally advanced cervical cancer. It compares standard chemotherapy and radiation with the same treatment plus a new drug, pembrolizumab (Keytruda), to see if it helps patients live longer and stops the cancer from growing.
Locally Advanced Cervical CancerNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ISIS 678354-CS5: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia.
This study is testing a new medicine, ISIS 678354, for people with very high levels of a type of fat in their blood called triglycerides. It aims to see if the medicine can lower these levels compared to a dummy medicine.
Severe Hypertriglyceridemia.Norway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS- 986205, Followed by Continued Post- Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer
This study is looking at new ways to treat bladder cancer that has grown into the muscle. It compares standard chemotherapy with chemotherapy plus new immunotherapy drugs (like Nivolumab) before and after surgery, to see which approach works best and is safest.
Bladder Cancer Muscle-Invasive Bladder CancerNorway - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia
This study is looking at a new medicine called HMPL-523 for adults with a blood condition called immune thrombocytopenia (ITP). It will check if the medicine is safe, how it works in the body, and if it helps people with ITP.
Primary immune thrombocytopenia (ITP)Norway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
This study looks at a new treatment, idecabtagene vicleucel (bb2121), for multiple myeloma that has come back or not responded to previous treatments. It compares this new treatment to standard options to see if it works better and is safe for patients aged 18 and over.
Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.Norway - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination with Bezafibrate in Subjects with Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid
This study is testing new combinations of medicines for a liver condition called Primary Biliary Cholangitis (PBC). We want to see if these combinations are safe and work better than current treatments, especially for people who haven't responded well to their usual medication.
Primary Biliary Cholangitis (PBC)Norway - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
An exploratory study to investigate the effect of FE 999302 when given during different time periods to women undergoing controlled ovarian stimulation with follitropin delta
This study looks at a new medicine called FE 999302, given to women having fertility treatment. It aims to see how giving the medicine at different times affects the treatment when they are also taking another fertility drug.
Infertility in women undergoing assisted reproductive technologies (ART)Norway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 (depemokimab) compared with mepolizumab or benralizumab
This study looks at a new medicine called depemokimab for severe asthma with high eosinophils. It compares it to existing treatments like mepolizumab and benralizumab over a year to see if it's just as good at preventing asthma attacks and improving control.
Severe asthma with an eosinophilic phenotypeNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)
This study is looking at the long-term safety of a new medicine called Iclepertin for people with schizophrenia. It's for those who have already taken part in earlier studies of this medicine. We want to see how safe it is over a longer period.
SchizophreniaNorway - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Norway - Ongoing, recruitingTherapeutic exploratory (Phase II)
HOVON 141 CLL: A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations.
This study is looking at a new combination treatment for chronic lymphocytic leukemia (CLL) that has come back or not responded to previous treatments. It aims to see how well these medicines keep the cancer from growing and how safe they are.
chronic lymphocytic leukemiaNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
MiBlock - Botulinum toxin type A blockade of the sphenopalatine ganglion in treatment-refractory chronic migraine
This study, called MiBlock, is looking into a new way to treat chronic migraine using an injection near a nerve in the face. It aims to see if this treatment can reduce the number of headache days compared to a dummy treatment, for people whose migraines haven't responded to other treatments.
Chronic migraineNorway